Acknowledgments
This work was supported in part by Grant 42387 from the Bill & Melinda Gates Foundation. The authors would like to thank Martin
Freide, PhD, for helpful discussions regarding method development.
CHRISTOPHER B. FOX is the lead formulation engineer, TIMOTHY S. DUTILL is the process development specialist II, JAMES CHESKO is a senior scientist, STEVE G. REED is the head of research and development, and THOMAS S. VEDVICK is the director of process sciences, all at the Infections Disease Research Institute, Seattle, WA, 206.330.2527, cfox@idri.org
RYAN C. ANDERSON, formerly of the Infections Disease Research Institute, currently is the account consultant—northern California, at Chemical
Abstracts Service, Columbus, OH.
References
1. Salem AK. CpG oligonucleotides as immunotherapeutic adjuvants: innovative applications and delivery strategies. Adv Drug
Del Rev. 2009;61:193–4.
2. Wack A, Baudner BC, Hilbert AK, Manini I, Nuti S, Tavarini, S, et al. Combination adjuvants for the induction of potent,
long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine. 2008;26:552–61.
3. Ott G, Singh M, Kazzaz J, Briones M, Soenawan E, Ugozzoli M, et al. A cationic sub-micron emulsion (MF59/DOTAP) is an
effective delivery system for DNA vaccines. J Control Rel. 2002;79:1–5.
4. Ioannou XP, Gomis SM, Hecker R, Babiuk LA, van Drunen Littel-van den Hurk S. Safety and efficacy of CpG-containing oligodeoxynucleotides
as immunological adjuvants in rabbits. Vaccine. 2003;21:4368–72.
5. Linghua Z, Xingshan T, Fengzhen Z. The efficacy of CpG oligodinucleotides, in combination with conventional adjuvants,
as immunological adjuvants to swine streptococcic septicemia vaccine in piglets in vivo. Int Immunopharm. 2006;6:1267–76.
6. Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis HL. CpG DNA can induce strong Th1 humoral and cell-mediated
immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci USA. 1998;95:15553–8.
7. Singh M, Chesko J, Kazzaz J, Ugozolli M, Malyala P, O'Hagan D. Surface-charged poly(lactide-co-glycolide) microparticles
as novel antigen delivery systems. In: Singh M, editor. Vaccine adjuvants and delivery systems. Hoboken, NJ: John Wiley &
Sons; 2007. p. 223–48.
8. Krieg AM. WO/2004/005476, WIPO, Nucleic acid compositions for stimulating immune responses, Coley Pharmaceutical Group,
Inc., 2004.
9. CpG ODN Information Sheet, Coley Pharmaceutical Group, 2006.
10. Hem SL, HogenEsch H. Aluminum-containing adjuvants: properties, formulation, and use. In: Singh M, editor. Vaccine adjuvants
and delivery systems. Hoboken, NJ: John Wiley & Sons; 2007. p. 81–114.
11. Lindblad EB. Aluminium adjuvants—in retrospect and prospect. Vaccine. 2004;22:3658–68.
12. Alhydrogel "85" 2% Certificate of Analysis. Brenntag Biosector. 2007.
13. Aebig JA, Mullen GED, Dobrescu G, Rausch K, Lamber L, Ajose-Popoola O, et al. Formulation of vaccines containing CpG
oligonucleotides and alum. J Immunol Methods 2007;323:139–46.
14. Kritsch CE, Berger A, Heinrich-Cseh C, Bugajska-Schretter A, Zauner W. Separation and quantification of a novel two-component
vaccine adjuvant. J Chromatogr B. 2005;822:263–70.
15. Dupuis M, Murphy TJ, Higgins D, Ugozzoli M, van Nest G, Ott G, et al. Dendritic cells internalize vaccine adjuvant after
intramuscular injection. Cell Immunol. 1998;186:18–27.
|
